Nkarta (NASDAQ:NKTX) Given New $14.00 Price Target at Stifel Nicolaus

Nkarta (NASDAQ:NKTX) had its price objective trimmed by Stifel Nicolaus from $15.00 to $14.00 in a report released on Thursday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other analysts have also recently commented on the company. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Nkarta in a research report on Thursday. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Nkarta in a research report on Thursday. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Nkarta presently has a consensus rating of “Buy” and an average price target of $14.86.

Nkarta Price Performance

NASDAQ:NKTX opened at $2.00 on Thursday. The company has a 50 day moving average price of $1.99 and a 200-day moving average price of $2.84. Nkarta has a 1-year low of $1.31 and a 1-year high of $11.84. The firm has a market cap of $141.92 million, a price-to-earnings ratio of -1.06 and a beta of 0.90.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings data on Wednesday, March 26th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. On average, sell-side analysts anticipate that Nkarta will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In other Nkarta news, CEO Paul J. Hastings sold 17,378 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total value of $38,231.60. Following the sale, the chief executive officer now directly owns 319,859 shares in the company, valued at $703,689.80. This trade represents a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 8.70% of the company’s stock.

Institutional Trading of Nkarta

Several institutional investors and hedge funds have recently made changes to their positions in the company. Invesco Ltd. acquired a new position in shares of Nkarta in the 4th quarter valued at $30,000. Sequoia Financial Advisors LLC acquired a new position in Nkarta in the fourth quarter valued at $31,000. Erste Asset Management GmbH acquired a new position in Nkarta in the third quarter valued at $33,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Nkarta in the fourth quarter valued at about $37,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Nkarta during the fourth quarter worth about $45,000. 80.54% of the stock is owned by hedge funds and other institutional investors.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.